Brian Smith, MD
Family Medicine · Sarepta, LANPI 1154395697
Payments from drug & device makers
Across 441 payments — averaging $16.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2K
- GSK$590
- Pfizer$527
- AstraZeneca$518
- Boehringer Ingelheim$492
- Novo Nordisk$487
- plus $3K from 27 others
What the payments were for
- Food & beverage$7,421100%
- Education$200%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 91 | $1,691 |
| GSK | 40 | $590 |
| Pfizer | 40 | $527 |
| AstraZeneca | 29 | $518 |
| Boehringer Ingelheim | 34 | $492 |
| Novo Nordisk | 33 | $487 |
| Otsuka America Pharmaceutical, Inc. | 22 | $458 |
| Takeda Pharmaceuticals U.S.A., Inc. | 20 | $423 |
| Lilly USA, LLC | 28 | $409 |
| Amgen | 14 | $237 |
| Bayer | 12 | $231 |
| Exact Sciences | 12 | $225 |
| Axsome Therapeutics, Inc. | 11 | $216 |
| Astellas Pharma US Inc | 9 | $146 |
| Abbott | 8 | $139 |
| Esperion Therapeutics, Inc. | 9 | $138 |
| Merck | 5 | $70 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 3 | $53 |
| Phathom Pharmaceuticals, Inc. | 3 | $50 |
| Lundbeck LLC | 2 | $45 |
| Ardelyx, Inc. | 2 | $45 |
| Medtronic | 2 | $41 |
| Idorsia Pharmaceuticals US Inc | 2 | $38 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $25 |
| Boston Scientific | 1 | $23 |
| Avanos Medical | 1 | $20 |
| Xeris Pharmaceuticals, Inc. | 1 | $20 |
| Johnson & Johnson | 1 | $15 |
| Kowa Pharmaceuticals America, Inc. | 1 | $14 |
| Neurelis, Inc. | 1 | $14 |
| Braintree Laboratories, Inc. | 1 | $14 |
| Sanofi Pasteur Inc. | 1 | $14 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $14 |
How this compares
$7,441 in reported general payments places this provider in the 85th percentile of 1,469 family medicine providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 233 | $120,203 |
| OzempicSemaglutide | 116 | $111,448 |
| RexultiBrexpiprazole | 95 | $87,321 |
| MounjaroTirzepatide | 82 | $85,110 |
| JardianceEmpagliflozin | 136 | $79,789 |
| FarxigaDapagliflozin Propanediol | 99 | $68,653 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 63 | $55,136 |
| VraylarCariprazine Hcl | 40 | $51,298 |
| RybelsusSemaglutide | 31 | $47,907 |
| XareltoRivaroxaban | 93 | $47,395 |
| QuliptaAtogepant | 24 | $25,801 |
| JanuviaSitagliptin Phosphate | 68 | $24,570 |
| TrintellixVortioxetine Hydrobromide | 59 | $23,860 |
| TrulicityDulaglutide | 20 | $23,611 |
| MultaqDronedarone Hcl | 24 | $16,355 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $487 | $159,355147 claims |
| PfizerEliquis | $527 | $120,203233 claims |
| Lilly USA, LLCMounjaro, Trulicity | $409 | $108,721102 claims |
| AbbVieVraylar, Qulipta, Linzess, Creon | $1,691 | $96,05799 claims |
| Boehringer IngelheimJardiance, Tradjenta, Spiriva Respimat | $492 | $94,873162 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $458 | $87,32195 claims |
| AstraZenecaFarxiga | $518 | $68,65399 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $590 | $60,63574 claims |
| Johnson & JohnsonXarelto | $15 | $47,39593 claims |
| MerckJanuvia | $70 | $24,57068 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $423 | $23,86059 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCTrulance | $14 | $13,51618 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,469 family medicine providers in Louisiana.
Other family medicine in Sarepta
- Clinton GuilloryMonroe$18.5M
- Jason MorrisLake Charles$18M
- Michael SeepLake Charles$9.1M
- William NaboursLake Charles$3M
- Ramon VargasKenner$2.1M
- Stephen JonesNew Orleans$513K
- Joshua WhatleyLake Charles$366K
- Richard JeansonneMandeville$362K
- Kristen ThomasNew Orleans$361K
- Clint WilsonBossier City$208K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.